Thermo Fisher Scientific Inc. $TMO Shares Sold by Essex Financial Services Inc.

Key Points

• Essex Financial Services Inc. reduced its stake in Thermo Fisher Scientific Inc. by 17.2% in Q2, leaving it with 7,957 shares valued at approximately $3,226,000.
• Research firms have varied ratings on Thermo Fisher, with price targets ranging from $480.00 to $561.00; the consensus rating is a "Moderate Buy".
• Thermo Fisher announced a quarterly dividend of $0.43 per share, with a yield of 0.4% and a dividend payout ratio of 9.95%.

Essex Financial Services Inc. lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 17.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 7,957 shares of the medical research company's stock after selling 1,651 shares during the quarter. Essex Financial Services Inc.'s holdings in Thermo Fisher Scientific were worth $3,226,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Mondrian Investment Partners LTD lifted its holdings in Thermo Fisher Scientific by 146.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock worth $106,738,000 after buying an additional 127,357 shares in the last quarter. Foresight Group Ltd Liability Partnership lifted its stake in shares of Thermo Fisher Scientific by 3,242.7% in the first quarter. Foresight Group Ltd Liability Partnership now owns 58,497 shares of the medical research company's stock worth $29,113,000 after acquiring an additional 56,747 shares in the last quarter. Advisors Capital Management LLC grew its stake in Thermo Fisher Scientific by 6.7% during the 1st quarter. Advisors Capital Management LLC now owns 127,011 shares of the medical research company's stock valued at $63,201,000 after purchasing an additional 7,967 shares in the last quarter. New England Research & Management Inc. raised its position in shares of Thermo Fisher Scientific by 28.6% in the 2nd quarter. New England Research & Management Inc. now owns 2,548 shares of the medical research company's stock valued at $1,033,000 after purchasing an additional 567 shares in the last quarter. Finally, Ilmarinen Mutual Pension Insurance Co boosted its stake in shares of Thermo Fisher Scientific by 5.3% during the 1st quarter. Ilmarinen Mutual Pension Insurance Co now owns 67,300 shares of the medical research company's stock valued at $33,488,000 after buying an additional 3,400 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on TMO. Evercore ISI cut their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Royal Bank Of Canada set a $561.00 target price on shares of Thermo Fisher Scientific and gave the company an "outperform" rating in a research note on Tuesday, September 2nd. William Blair began coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an "outperform" rating for the company. Barclays raised Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $490.00 to $550.00 in a report on Thursday, September 11th. Finally, Wells Fargo & Company lowered their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a report on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $588.35.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock valued at $14,182,963 in the last ninety days. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Down 0.4%

NYSE:TMO opened at $467.91 on Thursday. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The stock has a 50 day moving average of $475.04 and a 200-day moving average of $448.83. The firm has a market capitalization of $176.69 billion, a PE ratio of 27.06, a price-to-earnings-growth ratio of 2.55 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $623.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the previous year, the firm posted $5.37 EPS. The business's revenue for the quarter was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.